London & Greater Philadelphia – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces its investment in an ...

GREATER PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and ...

Engineered viruses are the delivery vehicle of choice for many genetic medicines, but they pose several problems. In addition to the risk of dangerous immune responses, these viruses don’t go to all ...

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four programs. The collaboration entails deploying ...

PHILADELPHIA, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David ...

Duchenne muscular dystrophy (DMD) and Type 1 diabetes couldn’t be more different: One is fairly rare and degenerative, while we hear about the other life-altering condition all the time. A new biotech ...

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases.

- Biopharma executive with nearly 30 years of experience will help deliver on company’s mission of transforming care for rare and genetic diseases through the use of its novel 3DNA® delivery platform ...

- Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors - Proceeds will enable Code Bio to ...